Galegenimab

戈莱恩尼单抗

Report date: 2023/03/18 20:00:22

Base Information

Drug NameGalegenimab
Drug Alias NameRG-6417RG-6147RO-7171009
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionSerine protease HTRA1 inhibitors
TargetsSerine protease HTRA1
Therapy Area/IndicationsGeographic AtrophyMacular Degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGenentech IncF. Hoffmann-La Roche Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGenentech Inc
Active IndicationsN/A
Inactive IndicationsGeographic AtrophyMacular Degeneration

Other Information

ATC CodeN/A
Related LinksN/A